Resource library

Resource library

Treatment resources for professionals

Comprehensive Leave Behind
See how adding ARESTIN to scaling and root planing (SRP) can help reduce pocket depth and play a role in the management of periodontal disease.

Tips for Use
This guide illustrates how to administer ARESTIN with step by step visuals.

Limitations of SRP Leave Behind
See how ARESTIN targets bacteria where instruments can’t reach.

Understanding Periodontal Treatment Acceptance Leave Behind
Learn what factors influence a patient’s acceptance of treatment.

2014 White Paper
Better understand the impact that coordinated in-office communications can have on patients’ understanding and acceptance of treatment recommendations.

2017 AAP Staging & Grading
Use the 2017 AAP Staging and Grading guidelines to help understand and communicate the severity, extent, and the anticipated progression of the patient's periodontal disease.

Limitations of SRP
Watch this video to learn about some of the limitations of SRP.
Spanish version
Prescribing Information (Spanish)

The Role of ARESTIN in Periodontal Treatment
Animated video shows how ARESTIN can help reduce pocket depth in patients with adult periodontitis.

How to Administer ARESTIN
Watch this animated video to see how to administer ARESTIN in 3 easy steps.

Patient education materials

Patient Brochure
This tool helps explain gum disease and your recommended treatment plan.
Spanish version
Prescribing Information (Spanish)

Flip Chart
Use this chair-side flip chart to explain periodontal disease to your patients, from diagnosis to treatment with ARESTIN + SRP.
Spanish version
Prescribing Information (Spanish)

Education Card
Use this education card to help your patients better understand periodontal disease.

Professional education

Shades of Gray: Crossing the Line in Diagnostics
Katrina Sanders, RDH, presents the clinical and diagnostic parameters surrounding the transition from gingivitis into periodontitis through an assessment of clinical findings.

When to Pull the Trigger: A Risky Behavior
Katrina Sanders, RDH, delivers an informative presentation on the role that risk assessment plays in implementing active periodontal therapy.

ARESTIN Rx Access

ARESTIN Prescription Form
Sign and fax this completed form to 1-855-630-9783 to submit a prescription.

ARESTIN Copay Assistance Patient Eligibility Form
Provide your patients with the terms and conditions for this special program, obtain their signature, and fax to 1-855-630-9783.

Spanish version
Prescribing Information (Spanish)

ARESTIN Sample Prescription Form
Refer to this template for guidance when completing the ARESTIN  Prescription Form. 

ARESTIN Rx Access Portal Tips
Learn how to quickly and accurately submit and track prescriptions using the ARESTIN Rx Access Online Portal.

Introducing ARESTIN Rx Access
Share information about the ARESTIN Rx Access Program with your patients.

ARESTIN Rx Access Prior Authorization
Learn the steps of the ARESTIN Rx Access prior authorization process.

Submitting Prescriptions
Gather helpful hints on submitting prescriptions to the ARESTIN Rx Access Program.

Tour the ARESTIN Rx Access Online Portal
Get a tour of the various components of the ARESTIN Rx Access online portal.

*Materials prepared by OraPharma.

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

This site is published by OraPharma, a division of Bausch Health Companies Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

OraPharma Logo®/TM are trademarks of Bausch Health Companies Inc. or its affiliates.
©2020 Bausch Health Companies Inc. or its affiliates.   ARE.0232.USA.20


CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

Click here for IMPORTANT SAFETY INFORMATION